Awakening gene therapy with Sleeping Beauty transposons

Jeffrey J. Essner; R. Scott McIvor; Perry B. Hackett

doi:10.1016/j.coph.2005.04.015

Awakening gene therapy with Sleeping Beauty transposons

Jeffrey J. Essner, R. Scott McIvor, Perry B. Hackett

Research output: Contribution to journal › Review article › peer-review

36 Scopus citations

Abstract

Sleeping Beauty transposons have the potential for use as chromosome-integrating vectors for non-viral gene therapy. Recent preclinical data from mouse models for human genetic disorders have shown efficacy for the Sleeping Beauty transposon system in the treatment of hemophilia, tyrosinemia type I, junctional epidermolysis bullosa and type 1 diabetes. Methods have also been developed to deliver Sleeping Beauty transposons to the lung, liver and tumors for treatments for cystic fibrosis, cardiovascular and metabolic diseases, and cancer. Recent studies characterizing site selection for integration and insertional mutagenesis indicate that the Sleeping Beauty transposon system may be a safer alternative than viral approaches for gene therapy.

Original language	English (US)
Pages (from-to)	513-519
Number of pages	7
Journal	Current Opinion in Pharmacology
Volume	5
Issue number	5 SPEC.ISS.
DOIs	https://doi.org/10.1016/j.coph.2005.04.015
State	Published - Oct 2005

Bibliographical note

Funding Information:
We thank Dr. Maura A McGrail for her thoughtful comments. The authors were supported by NIH grants P01 HD32652-07 (PBH and RSM) and R43 HL076908-01.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.coph.2005.04.015

OpenUrl availability

Full text

Cite this

@article{bbb9ef711e3a4ea7b626a398390a07b5,

title = "Awakening gene therapy with Sleeping Beauty transposons",

abstract = "Sleeping Beauty transposons have the potential for use as chromosome-integrating vectors for non-viral gene therapy. Recent preclinical data from mouse models for human genetic disorders have shown efficacy for the Sleeping Beauty transposon system in the treatment of hemophilia, tyrosinemia type I, junctional epidermolysis bullosa and type 1 diabetes. Methods have also been developed to deliver Sleeping Beauty transposons to the lung, liver and tumors for treatments for cystic fibrosis, cardiovascular and metabolic diseases, and cancer. Recent studies characterizing site selection for integration and insertional mutagenesis indicate that the Sleeping Beauty transposon system may be a safer alternative than viral approaches for gene therapy.",

author = "Essner, {Jeffrey J.} and McIvor, {R. Scott} and Hackett, {Perry B.}",

note = "Funding Information: We thank Dr. Maura A McGrail for her thoughtful comments. The authors were supported by NIH grants P01 HD32652-07 (PBH and RSM) and R43 HL076908-01.",

year = "2005",

month = oct,

doi = "10.1016/j.coph.2005.04.015",

language = "English (US)",

volume = "5",

pages = "513--519",

journal = "Current Opinion in Pharmacology",

issn = "1471-4892",

publisher = "Elsevier BV",

number = "5 SPEC.ISS.",

}

TY - JOUR

T1 - Awakening gene therapy with Sleeping Beauty transposons

AU - Essner, Jeffrey J.

AU - McIvor, R. Scott

AU - Hackett, Perry B.

N1 - Funding Information: We thank Dr. Maura A McGrail for her thoughtful comments. The authors were supported by NIH grants P01 HD32652-07 (PBH and RSM) and R43 HL076908-01.

PY - 2005/10

Y1 - 2005/10

N2 - Sleeping Beauty transposons have the potential for use as chromosome-integrating vectors for non-viral gene therapy. Recent preclinical data from mouse models for human genetic disorders have shown efficacy for the Sleeping Beauty transposon system in the treatment of hemophilia, tyrosinemia type I, junctional epidermolysis bullosa and type 1 diabetes. Methods have also been developed to deliver Sleeping Beauty transposons to the lung, liver and tumors for treatments for cystic fibrosis, cardiovascular and metabolic diseases, and cancer. Recent studies characterizing site selection for integration and insertional mutagenesis indicate that the Sleeping Beauty transposon system may be a safer alternative than viral approaches for gene therapy.

AB - Sleeping Beauty transposons have the potential for use as chromosome-integrating vectors for non-viral gene therapy. Recent preclinical data from mouse models for human genetic disorders have shown efficacy for the Sleeping Beauty transposon system in the treatment of hemophilia, tyrosinemia type I, junctional epidermolysis bullosa and type 1 diabetes. Methods have also been developed to deliver Sleeping Beauty transposons to the lung, liver and tumors for treatments for cystic fibrosis, cardiovascular and metabolic diseases, and cancer. Recent studies characterizing site selection for integration and insertional mutagenesis indicate that the Sleeping Beauty transposon system may be a safer alternative than viral approaches for gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=24344495491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344495491&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2005.04.015

DO - 10.1016/j.coph.2005.04.015

M3 - Review article

C2 - 16084771

AN - SCOPUS:24344495491

SN - 1471-4892

VL - 5

SP - 513

EP - 519

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

IS - 5 SPEC.ISS.

ER -

Awakening gene therapy with Sleeping Beauty transposons

Abstract

Bibliographical note

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this